title: Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for dupuytren contracture.
abstract: OBJECTIVE
  We undertook a cost-utility analysis to compare traditional fasciectomy for Dupuytren with 2 new treatments, needle aponeurotomy and collagenase injection.
  
  
  METHODS
  We constructed an expected-value decision analysis model with an arm representing each treatment. A survey was administered to a cohort of 50 consecutive subjects to determine utilities of different interventions. We conducted multiple sensitivity analyses to assess the impact of varying the rate of disease recurrence in each arm of the analysis as well as the cost of the collagenase injection. The threshold for a cost-effective treatment is based on the traditional willingness-to-pay of $50,000 per quality-adjusted life years (QALY) gained.
  
  
  RESULTS
  The cost of open partial fasciectomy was $820,114 per QALY gained over no treatment. The cost of needle aponeurotomy was $96,474 per QALY gained versus no treatment. When we performed a sensitivity analysis and set the success rate at 100%, the cost of needle aponeurotomy was $49,631. When needle aponeurotomy was performed without surgical center or anesthesia costs and with reduced hand therapy, the cost was $36,570. When a complete collagenase injection series was priced at $250, the cost was $31,856 per QALY gained. When the injection series was priced at $945, the cost was $49,995 per QALY gained. At the market price of $5,400 per injection, the cost was $166,268 per QALY gained.
  
  
  CONCLUSIONS
  In the current model, open partial fasciectomy is not cost-effective. Needle aponeurotomy is cost-effective if the success rate is high. Collagenase injection is cost-effective when priced under $945.
  
  
  METHODS
  Economic and Decision Analysis II.
authors: Department of Orthopaedic Surgery and the Section of Plastic Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. nealchen@yahoo.com
authors: Neal C
authors: NC
authors: Chen
authors: Melissa J
authors: MJ
authors: Shauver
authors: Kevin C
authors: KC
authors: Chung
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D015331:Cohort Studies; D017364:Collagenases / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D003661:Decision Support Techniques; D004387:Dupuytren Contracture / Q000191:economics* / Q000601:surgery* / Q000628:therapy; D000071938:Fasciotomy; D005260:Female; D005500:Follow-Up Studies; D017721:Hospital Costs; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures / Q000191:economics / Q000379:methods; D019637:Orthopedic Procedures / Q000191:economics* / Q000379:methods; D019057:Quality-Adjusted Life Years; D020127:Recovery of Function; D012008:Recurrence; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D017364:Collagenases